About
Technology
Issues
FAQ
Links
Official Page
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.
